AU2026202293A1 — Methods of treating Rett syndrome using fenfluramine

USPTO Abstract

A method of treating and/or preventing symptoms of Rett syndrome (RTT) in a patient such as a patient previously diagnosed with Rett syndrome, by administering an effective dose of a 5-HTlD, 5-HT2A, 5-HT2C or sigma-1 receptor agonist (e.g., fenfluramine or its pharmaceutically acceptable salt) to that patient. RTT patients are treated at a preferred dose of less than about 1.0 mg/kg/day and may be administered as fenfluramine in an amount of between 0.2 to 0.8 mg/kg/day, to a maximum of 30 mg/day in a liquid oral dose. 20 26 20 22 93 25 M ar 2 02 6 2 0 2 6 2 0 2 2 9 3 2 5 M a r 2 0 2 6